CJC-1295 DAC is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
CJC-1295 DAC (CJC-1295 with Drug Affinity Complex) is researched primarily for sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis, improved body composition, increased muscle mass. The only GHRH analog with extended half-life allowing once-weekly dosing — but this convenience comes at the cost of sustained supraphysiological GH levels that bypass natural feedback, which is why most researchers prefer the no-DAC version. It belongs to the GHRH analog with extended half-life category of compounds.
What Is CJC-1295 DAC?
CJC-1295 DAC (CJC-1295 with Drug Affinity Complex) is a GHRH analog with extended half-life. Synthetic GHRH analog with four amino acid substitutions conjugated to a drug affinity complex that binds endogenous albumin.
The only GHRH analog with extended half-life allowing once-weekly dosing — but this convenience comes at the cost of sustained supraphysiological GH levels that bypass natural feedback, which is why most researchers prefer the no-DAC version. It has attracted significant research interest for its potential effects on sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis, improved body composition, increased muscle mass.
How Does CJC-1295 DAC Produce These Benefits?
Binds GHRH receptors on pituitary somatotrophs to stimulate GH synthesis and secretion. The DAC module covalently binds to endogenous albumin, extending the half-life to 6-8 days while maintaining receptor bioavailability. This creates sustained, elevated GH levels rather than the pulsatile release seen with CJC-1295 no DAC.
This multi-pathway activity is why CJC-1295 DAC shows potential across several different applications rather than being limited to a single use case.
Can CJC-1295 DAC Help With Sustained Gh Elevation?
Research suggests CJC-1295 DAC may support sustained GH elevation through its ghrh analog with extended half-life activity. Single dose increases plasma GH 2-10 fold for 6+ days and IGF-1 0.5-3 fold for 9-11 days in humans. Multiple clinical trials demonstrated sustained dose-dependent GH/IGF-1 elevation. Reached Phase II before discontinuation.
Protocols targeting sustained GH elevation typically use 1-2 mg per injection administered once or twice weekly for 12-16 weeks.
Can CJC-1295 DAC Help With Elevated Igf-1 Levels?
Research suggests CJC-1295 DAC may support elevated IGF-1 levels through its ghrh analog with extended half-life activity. Single dose increases plasma GH 2-10 fold for 6+ days and IGF-1 0.5-3 fold for 9-11 days in humans. Multiple clinical trials demonstrated sustained dose-dependent GH/IGF-1 elevation. Reached Phase II before discontinuation.
Protocols targeting elevated IGF-1 levels typically use 1-2 mg per injection administered once or twice weekly for 12-16 weeks.
Can CJC-1295 DAC Help With Enhanced Protein Synthesis?
Research suggests CJC-1295 DAC may support enhanced protein synthesis through its ghrh analog with extended half-life activity. Single dose increases plasma GH 2-10 fold for 6+ days and IGF-1 0.5-3 fold for 9-11 days in humans. Multiple clinical trials demonstrated sustained dose-dependent GH/IGF-1 elevation. Reached Phase II before discontinuation.
Protocols targeting enhanced protein synthesis typically use 1-2 mg per injection administered once or twice weekly for 12-16 weeks.
Can CJC-1295 DAC Help With Improved Body Composition?
Research suggests CJC-1295 DAC may support improved body composition through its ghrh analog with extended half-life activity. Single dose increases plasma GH 2-10 fold for 6+ days and IGF-1 0.5-3 fold for 9-11 days in humans. Multiple clinical trials demonstrated sustained dose-dependent GH/IGF-1 elevation. Reached Phase II before discontinuation.
Protocols targeting improved body composition typically use 1-2 mg per injection administered once or twice weekly for 12-16 weeks.
Can CJC-1295 DAC Help With Increased Muscle Mass?
Research suggests CJC-1295 DAC may support increased muscle mass through its ghrh analog with extended half-life activity. Single dose increases plasma GH 2-10 fold for 6+ days and IGF-1 0.5-3 fold for 9-11 days in humans. Multiple clinical trials demonstrated sustained dose-dependent GH/IGF-1 elevation. Reached Phase II before discontinuation.
Protocols targeting increased muscle mass typically use 1-2 mg per injection administered once or twice weekly for 12-16 weeks.
Can Stacking Enhance CJC-1295 DAC Benefits?
Synergizes with GHRP-6 or GHRP-2 for amplified GH pulse amplitude. The sustained release makes it less ideal for stacking than CJC-1295 no DAC, which preserves natural pulsatility.
See our CJC-1295 DAC stacking guide for detailed combination protocols.
What Is the Bottom Line on CJC-1295 DAC Benefits?
CJC-1295 DAC is researched for sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis, improved body composition, increased muscle mass. The evidence base includes: Single dose increases plasma GH 2-10 fold for 6+ days and IGF-1 0.5-3 fold for 9-11 days in humans. Multiple clinical trials demonstrated sustained dose-dependent GH/IGF-1 elevation. Reached Phase II before discontinuation.
CJC-1295 DAC is not fda-approved. development discontinued post-phase ii. wada banned. available as research peptide. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
CJC-1295 DAC : Benefits, Dosage, Side Effects & Research
Related Reading
- CJC-1295 DAC Dosage Guide
- CJC-1295 DAC Side Effects
- CJC-1295 DAC Stacking Guide
- CJC-1295 DAC Cycle Guide
- CJC-1295 DAC Research
- CJC-1295 Complete Guide
Calculate Your CJC-1295 DAC Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for CJC-1295 DAC.
Open Calculator →Research-Grade Sourcing
If you're going to research CJC-1295 DAC, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is CJC-1295 DAC?
CJC-1295 DAC (CJC-1295 with Drug Affinity Complex) is a GHRH analog with extended half-life. Synthetic GHRH analog with four amino acid substitutions conjugated to a drug affinity complex that binds endogenous albumin. It is researched for sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis, improved body composition, increased muscle mass.
What is the recommended CJC-1295 DAC dosage?
Common dosages: 1-2 mg per injection administered once or twice weekly via subcutaneous injection. Cycle length: 12-16 weeks. Half-life: 6-8 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of CJC-1295 DAC?
Water retention, joint aches, fluid retention, mild headache. Sustained GH elevation may cause more pronounced side effects than pulsatile release versions. One subject death in Phase II trial was attributed to unrelated coronary artery disease.
Is CJC-1295 DAC safe?
CJC-1295 DAC has shown a preliminary safety profile in research. Not FDA-approved. Development discontinued post-Phase II. WADA banned. Available as research peptide. All research should follow appropriate safety protocols.